Bosun Asset Management’s Moderna MRNA Stock Holding History

Bosun Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500	Closed	-$60.8K	–	153
2023 Q2	$60.8K	Buy	+500	New	+$66.7K	0.06%	161

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Bosun Asset Management's MRNA Position: Q3 2023 in Review

Bosun Asset Management sold out of Moderna (MRNA) in Q3 2023, closing a stake of 500 shares — an estimated $60.8K sold.

Bosun Asset Management first reported a position in MRNA in Q2 2023 and held it in 1 quarter. The position peaked at $60.8K in Q2 2023. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

Bosun Asset Management reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
Bosun Asset Management sold 500 Moderna shares in Q3 2023, an estimated $60.8K.
Bosun Asset Management first reported a position in Moderna in Q2 2023 and held it in 1 quarter.
Bosun Asset Management's Moderna position peaked at $60.8K in Q2 2023.
889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Bosun Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.